Literature DB >> 3732336

The dexamethasone suppression test in depressive and schizophrenic patients under controlled treatment conditions.

H J Möller, W Kissling, P Bottermann.   

Abstract

Endogenous depressive and schizophrenic patients demonstrated the same frequency of pathological DST results after admission. After 3 weeks of psychopharmacological treatment the percentage of abnormal DST results was significantly reduced in both groups, although the treatment conditions were different. A correlation between the DST non-suppression and intensity of depression was observed only in the depressive group, not in the schizophrenic group. Normalization of DST results in depressive patients was mostly associated with an improvement of depressive scores. Other course patterns of DST results did not seem to be combined with psychopathological changes. From this data it has to be concluded that DST non-suppression is in some part related to depressive symptoms, but is not characteristic or specific for endogenous depression or for depressivity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732336     DOI: 10.1007/bf00515912

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  32 in total

1.  Dexamethasone test in alcoholics.

Authors:  G F Oxenkrug
Journal:  Lancet       Date:  1978-10-07       Impact factor: 79.321

2.  Dexamethasone suppression test predicts response to nomifensine or amitriptyline.

Authors:  H Beckmann; B Holzmüller; P Fleckenstein
Journal:  Br J Psychiatry       Date:  1984-04       Impact factor: 9.319

3.  Fluctuating postdexamethasone cortisol levels in a patient with melancholia.

Authors:  A J Rothschild; A F Schatzberg
Journal:  Am J Psychiatry       Date:  1982-01       Impact factor: 18.112

4.  The limited utility of the dexamethasone suppression test for the diagnostic process in psychiatry.

Authors:  M Berger; K M Pirke; P Doerr; J C Krieg; D von Zerssen
Journal:  Br J Psychiatry       Date:  1984-10       Impact factor: 9.319

5.  Genetic subtypes of unipolar primary depressive illness distinguished by hypothalamic-pituitary-adrenal axis activity.

Authors:  M A Schlesser; G Winokur; B M Sherman
Journal:  Lancet       Date:  1979-04-07       Impact factor: 79.321

6.  The dexamethasone suppression test as a predictor of antidepressant response.

Authors:  J D Amsterdam; A Winokur; S Bryant; J Larkin; K Rickels
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Neuroendocrinological and neurophysiological studies in major depressive disorders: are there biological markers for the endogenous subtype?

Authors:  M Berger; P Doerr; R Lund; T Bronisch; D von Zerssen
Journal:  Biol Psychiatry       Date:  1982-11       Impact factor: 13.382

8.  The dexamethasone suppression test in mania.

Authors:  P M Graham; J Booth; G Boranga; S Galhenage; C M Myers; C L Teoh; L S Cox
Journal:  J Affect Disord       Date:  1982-09       Impact factor: 4.839

9.  Dexamethasone suppression test and cortisol circadian rhythm in primary degenerative dementia.

Authors:  M Raskind; E Peskind; M F Rivard; R Veith; R Barnes
Journal:  Am J Psychiatry       Date:  1982-11       Impact factor: 18.112

10.  Dexamethasone suppression testing of alcoholics.

Authors:  C M Swartz; F J Dunner
Journal:  Arch Gen Psychiatry       Date:  1982-11
View more
  2 in total

1.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

2.  Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients.

Authors:  H J Möller; G Fischer; D von Zerssen
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1987
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.